University of Maryland Greenebaum Comprehensive Cancer Center.
Department of Medicine.
Curr Opin Oncol. 2022 May 1;34(3):243-252. doi: 10.1097/CCO.0000000000000829.
The aim of the review is to provide an update on the current and evolving approaches to diagnosing the challenging clinical entity of renal oncocytoma.
Renal oncocytoma is being increasingly recognized among patients with renal masses, and it can be found in up to 50% of benign small renal masses (SRMs) less than 4 cm. Renal oncocytomas have benign clinical biology but distinguishing them from some of the other renal masses with more malignant potential can be challenging due to overlapping imaging, histologic, and immunophenotypic characteristics. Increasing integration of various imaging modalities, histologic characteristics, cytogenetics, and molecular and metabolic signatures is helping better define and characterize renal masses.
Evolving and complementary diagnostic approaches, including at the molecular level, are continuing to help refine the classification of renal tumors, with implications on their clinical behavior and ultimately clinical management.
本文旨在提供对目前诊断肾嗜酸细胞瘤这一具有挑战性的临床实体的方法的更新。
随着对肾肿瘤患者认识的不断提高,肾嗜酸细胞瘤在直径小于 4cm 的 50%良性小肾肿瘤(SRM)中被发现。肾嗜酸细胞瘤具有良性的临床生物学特性,但由于其影像学、组织学和免疫表型特征存在重叠,因此与其他一些具有更大恶性潜能的肾肿瘤区分具有一定的挑战性。各种影像学方式、组织学特征、细胞遗传学以及分子和代谢特征的不断整合,有助于更好地定义和描述肾肿瘤。
不断发展和互补的诊断方法,包括分子水平的方法,有助于完善肾肿瘤的分类,这对其临床行为,最终对临床管理具有重要意义。